Susmed Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 50

Employees

  • Stock Symbol
  • 4263

Stock Symbol

  • Share Price
  • $1.58
  • (As of Friday Closing)

Susmed General Information

Description

Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • MFPR Nihonbashi Honcho Building 10th Floor
  • 3-7-2 Nihonbashi Honcho, Chuo-ku
  • Tokyo, 103-0023
  • Japan
Primary Industry
Other Healthcare Technology Systems
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
TKS
Corporate Office
  • MFPR Nihonbashi Honcho Building 10th Floor
  • 3-7-2 Nihonbashi Honcho, Chuo-ku
  • Tokyo, 103-0023
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Susmed Stock Performance

As of 13-Nov-2026, Susmed’s stock price is $1.58. Its current market cap is $26.6M with 16.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.58 $1.54 $1.51 - $7.73 $26.6M 16.9M 155K -$0.15

Susmed Financials Summary

As of 30-Jun-2026, Susmed has a trailing 12-month revenue of $3.22M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 65,838 65,838 39,614 31,631
Revenue 3,220 3,220 3,093 2,297
EBITDA (2,388) (2,388) (1,932) (2,349)
Net Income (2,478) (2,478) (1,994) (2,397)
Total Assets 26,049 26,049 31,151 30,649
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Susmed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Susmed‘s full profile, request access.

Request a free trial

Susmed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Susmed‘s full profile, request access.

Request a free trial

Susmed Patents

Susmed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026159836-A1 Thought transmission assistance system, thought transmission assistance device, and thought transmission assistance program Pending 23-Jan-2025
WO-2026141050-A1 Information processing device and application program Pending 24-Dec-2024
WO-2026042718-A1 Cognitive behavioral therapy assistance device, cognitive behavioral therapy assistance system, and cognitive behavioral therapy assistance program Pending 19-Aug-2024
WO-2025248743-A1 Llm utilization system, llm service provision device, and llm service provision method Pending 31-May-2024
WO-2025203306-A1 Treatment assistance device, treatment assistance program, and treatment assistance system Pending 27-Mar-2024
To view Susmed’s complete patent history, request access »

Susmed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Susmed ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Susmed’s complete esg history, request access »

Susmed FAQs

  • When was Susmed founded?

    Susmed was founded in 2015.

  • Where is Susmed headquartered?

    Susmed is headquartered in Tokyo, Japan.

  • What is the size of Susmed?

    Susmed has 50 total employees.

  • What industry is Susmed in?

    Susmed’s primary industry is Other Healthcare Technology Systems.

  • Is Susmed a private or public company?

    Susmed is a Public company.

  • What is Susmed’s stock symbol?

    The ticker symbol for Susmed is 4263.

  • What is the current stock price of Susmed?

    As of 13-Nov-2026 the stock price of Susmed is $1.58.

  • What is the current market cap of Susmed?

    The current market capitalization of Susmed is $26.6M.

  • What is Susmed’s current revenue?

    The trailing twelve month revenue for Susmed is $3.22M.

  • What is Susmed’s annual earnings per share (EPS)?

    Susmed’s EPS for 12 months was -$0.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process